Ebisawa, Kazutoshi
Masamoto, Yosuke
Tokushige, Junji
Nishi, Hiroshi
Honda, Kenjiro
Hinata, Munetoshi
Toyama, Kazuhiro
Nangaku, Masaomi
Kurokawa, Mineo
Article History
Received: 14 December 2018
Accepted: 14 January 2019
First Online: 13 February 2019
Compliance with ethical standards
: Full informed consent was obtained from the patient in this report for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Kazuhiro Toyama has the following financial relationship to disclose. Honoraria (lecture fee) from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Masaomi Nangaku has the following financial relationships to disclose. Honoraria (lecture fee) and research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Mineo Kurokawa has the following financial relationship to disclose. Research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). The other authors (Drs K.E., Y.M., J.T., H.N., K.H., M.H.) declared that they had no relevant financial relationships to disclose.